Hypertension was targeted as a manifestation of ADPKD in the Halt Progression of Polycystic Kidney Disease (HALT-PKD) study, a clinical trial studying the intensive blockade of the renin-angiotensin system with combination ACEIs and angiotensin receptor blockers (ARBs). This evidence concerns the gene REN and Hypertension.